摘要
Abstract
Objective To analyze the efficacy and safety of Vardenafil de-escalation therapy for chronic prostatitis (CP) with erectile dysfunction (ED) and to explore the clinical application value of the scheme. Methods A total of 240 patients of CP with ED treated in our hospital from January 2013 to January 2016 were enrolled as the research objects. According to the random number table method, they were divided into observation group and control group, each with 120 patients. Both groups received Vardenafil treatment on the basis of conventional treatment for CP. The control group was treated with Vardenafil 10 mg/time, once every other day for 3 months. The observation group was given Vardenafil de-escalation therapy for 3 months, the initial dosage was 20 mg once every other day for 1 month, then the dosage decreased to 10 mg once every other day for 1 month, finally reduced to 5 mg once every other day for 1 month. After treatment for 1, 2 and 3 months, the international index of erectile function (IIEF), daily insertion success rate and success rate of completing intercourse and international prostatitis symptom score index table (NIH-CPSI) changes were recorded in the two groups of patients, and the adverse reactions were also recorded. The clinical efficacy and safety of the two therapies were compared. Results Before treatment, the IIEF-5 score, the NIH-CPSI score, the daily success rate of insertion or the success rate of completing intercourse was not statistically different between the two groups (P > 0.05). After treatment, the IIEF-5 score, the daily success rate of insertion and the success rate of completing intercourse increased and the NIH-CPSI score decreased in both groups, the differences were statistically significant (P < 0.05); however, the IIEF-5 score, the NIH-CPSI score, the daily insertion success rate, the success rate of completing intercourse after treatment were not statistically different between the two groups (P > 0.05). In both groups, the SDS score and the SAS score after treatment were lower than those before treatment, the indexes decreased more significantly in the observation group, the differences were statistically significant (P < 0.05). The incidences of adverse reactions were not statistically different in both groups 1 month after treatment (P > 0.05). In the observation group, the incidences of side effects after treatment for 2 and 3 months were significantly lower than those 1 month after treatment (P < 0.05). In the control group, there were no significant differences in the incidences of adverse reactions after treatment for 1 to 3 months (P > 0.05). The total effective rate was 90.83% in the observation group and 94.17% in the control group, the difference was not statistically significant (P > 0.05). Conclusions Vardenafil de-escalation therapy for CP with ED can guarantee the clinical curative effect and further reduce side effects during treatment, improve the psychological state of the patients. It has better security than large-dosage continuous therapy, and is worthy to be popularized.关键词
伐地那非/降阶梯治疗/慢性前列腺炎/勃起功能障碍/疗效/安全性Key words
Vardenafil/step down therapy/chronic prostatitis/erectile dysfunction/efficacy/safety分类
医药卫生
